Toggle menu
Toggle preferences menu
Toggle personal menu
Not logged in
Your IP address will be publicly visible if you make any edits.

Methamphetamine

Checked
From Pharmacopedia
Psychostimulant, Amphetamine
Methamphetamine
Desoxyn
Methamphetamine is a CNS stimulant of the amphetamine class. It is FDA-approved (as Desoxyn) for attention-deficit hyperactivity disorder and short-term management of obesity. It is a Schedule II controlled substance in the United States.

Experience

πŸ‘₯ No personal reports yet
βš• No clinical reports yet

Log in to add your own experience.

Problems

<indication slug="adhd" title="ADHD in children, adolescents, and adults" author="MDElliottMD"/> <indication slug="obesity" title="Obesity (short-term)" author="MDElliottMD"/>

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

  • Attention and focusπŸ‘€ no reports yetβš•οΈ no reports yet
  • WakefulnessπŸ‘€ no reports yetβš•οΈ no reports yet
  • Motivation and driveπŸ‘€ no reports yetβš•οΈ no reports yet
  • Mild euphoriaπŸ‘€ no reports yetβš•οΈ no reports yet
  • Decreased appetite/AnorexiaπŸ‘€ no reports yetβš•οΈ no reports yet
  • Dry mouthπŸ‘€ no reports yetβš•οΈ no reports yet
  • Elevated heart rate / blood pressureπŸ‘€ no reports yetβš•οΈ no reports yet
  • InsomniaπŸ‘€ no reports yetβš•οΈ no reports yet
  • IrritabilityπŸ‘€ no reports yetβš•οΈ no reports yet
  • AnxietyπŸ‘€ no reports yetβš•οΈ no reports yet
  • HeadacheπŸ‘€ no reports yetβš•οΈ no reports yet
  • Weight lossπŸ‘€ no reports yetβš•οΈ no reports yet
  • PalpitationsπŸ‘€ no reports yetβš•οΈ no reports yet
  • Jaw clenching / bruxismπŸ‘€ no reports yetβš•οΈ no reports yet
  • Stereotyped behaviorsπŸ‘€ no reports yetβš•οΈ no reports yet
  • AgitationπŸ‘€ no reports yetβš•οΈ no reports yet
  • PsychosisπŸ‘€ no reports yetβš•οΈ no reports yet
  • ManiaπŸ‘€ no reports yetβš•οΈ no reports yet
  • Dependence / misuseπŸ‘€ no reports yetβš•οΈ no reports yet
  • ToleranceπŸ‘€ no reports yetβš•οΈ no reports yet
  • Serious cardiac eventπŸ‘€ no reports yetβš•οΈ no reports yet
  • Seizure/Epileptic fitπŸ‘€ no reports yetβš•οΈ no reports yet
  • HyperthermiaπŸ‘€ no reports yetβš•οΈ no reports yet
  • Serotonin syndromeπŸ‘€ no reports yetβš•οΈ no reports yet
  • Withdrawal/Discontinuation SyndromeπŸ‘€ no reports yetβš•οΈ no reports yet

+ Add an effect

Pharmacokinetics

Metabolism

Hepatic metabolism includes N-demethylation to amphetamine (an active metabolite).

Elimination

Urinary elimination is pH-dependent.

Pharmacodynamics

Methamphetamine acts at monoaminergic terminals as a releasing agent via TAAR1 agonism, VMAT2 substrate activity, and DAT/NET reverse transport. Secondary mechanisms include weak monoamine reuptake inhibition.

Interactions

  • MAOIs β€” contraindicated (per label)
  • Acidifying agents β€” increase urinary clearance
  • Alkalinizing agents β€” decrease urinary clearance
No interactions reported yet.

Pregnancy and lactation

Category C per Desoxyn label.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

See also

Mixed amphetamine salts, Dextroamphetamine, Lisdexamfetamine, Methylphenidate, Dexmethylphenidate, Modafinil

References

Structure of Methamphetamine
Summary
Classes
Psychostimulant, Amphetamine
Common uses
Inattention0, Hyperactivity0, Obesity0
Pharmacy
Starting dose
5 mg PO
Preparations
Desoxyn 5 mg tabs
US FDA Max
25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label)
Pharmacology
Routes
Oral (prescribed)
Pregnancy
Category C (per Desoxyn label)
Legal status
Schedule II
Purported mechanism
Monoamine releasing agent β€” TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport